anonymous
Guest
anonymous
Guest
Debate rages over Alzheimer’s drug lecanemab as UK limits approval
Debate rages over Alzheimer’s drug lecanemab as UK limits approval
The Alzheimer’s disease drug lecanemab (sold as Leqembi) is one of the first shown to slow cognitive decline in people. But the extent of its benefits is hotly debated, it has potential side effects and it’s expensive.
Debate rages over Alzheimer’s drug lecanemab as UK limits approval
The Alzheimer’s disease drug lecanemab (sold as Leqembi) is one of the first shown to slow cognitive decline in people. But the extent of its benefits is hotly debated, it has potential side effects and it’s expensive.